Search

Your search keyword '"Ley, D."' showing total 698 results
Start Over Author "Ley, D."
698 results on '"Ley, D."'

12. Assessment of Brain Injury and Brain Volumes after Posthemorrhagic Ventricular Dilatation: A Nested Substudy of the Randomized Controlled ELVIS Trial

Author

Han, K., Woerdeman, P., ter Horst, H.J., Dijkman, K.P., Ley, D., Fellman, V., de Haan, T.R., Brouwer, A.J., van ‘t Verlaat, E., Govaert, P., Smit, B.J., Agut Quijano, T., Barcik, U., Mathur, A., Graca, A.M., Cizmeci, Mehmet N., Khalili, Nadieh, Claessens, Nathalie H.P., Groenendaal, Floris, Liem, Kian D., Heep, Axel, Benavente-Fernández, Isabel, van Straaten, Henrica L.M., van Wezel-Meijler, Gerda, Steggerda, Sylke J., Dudink, Jeroen, Išgum, Ivana, Whitelaw, Andrew, Benders, Manon J.N.L., and de Vries, Linda S.

Published
2019
Full Text
View/download PDF

20. P207 Colonic location at diagnosis of pediatric-onset Crohn’s disease is associated with a pejorative disease course: a two decades population-based study

Author

Fumery, Mathurin, Savoye, G, Ley, D, Dupont-Lucas, C, Bertrand, V, Wils, P, Guillon, N, Sarter, H, Gower-Rousseau, C, Turck, D, Leroyer, A, CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Groupe Hospitalier du Havre, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Epidémiologie et de Santé Publique [Lille], Maison Régionale de la Recherche Clinique [Lille], Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background Crohn's disease (CD) location would influence the risk of complications and therapeutic strategies. The objective of this study was to compare the clinical presentation at diagnosis and the natural history of colonic CD in comparison to ileal CD and ulcerative colitis (UC) in pediatric-onset inflammatory bowel disease. Methods All children (< 17 years) with a diagnosis of CD or UC made between 1988 and 2011 in a population-based registry were followed retrospectively until 2013. Presentation at diagnosis, risks of complicated disease, surgery, hospitalization and exposure to treatments in ileal CD (L1), colonic CD (L2) and UC were compared. Disease location was defined at diagnosis. In case of extension of the disease (L1 or L2 to L3), follow-up was censored. Results A total of 215 L1 patients, 234 L2 patients and 337 UC patients were included. At diagnosis, the proportion of males (L1 53.5%; L2 53.4%; UC 42.7%; p=0.012), age at diagnosis (15.0; 13.7; 14.0 years; p=0.003), family history of IBD (12.6%; 12.7%; 5.0%; p=0.005), diagnostic delay (3.0; 3.0; 2.0 months; p=0.001) and smoking prevalence (11.6%; 8.1%; 5.6%; p=0.041) were different between the three groups. Bloody stool and diarrhea at diagnosis was observed in respectively 14.9%, 44.4%, and 91.1% (p < 0.001) and 47.0%, 71.8%, and 65.0% (p < 0.001) of L1, L2 and UC. At diagnosis, granuloma was identified in 12.6% of L1 patients and 31.2% of L2 patients (p

Published
2023

21. P155 Natural history of anal stricture in pediatric-onset Crohn’s disease: a two-decades population-based study

Author

Mortreux, P, primary, Leroyer, A, additional, Ley, D, additional, Dupont-Lucas, C, additional, Bertrand, V, additional, Wils, P, additional, Coevoet, H, additional, Paupard, T, additional, Gower-Rousseau, C, additional, Siproudhis, L, additional, Guillon, N, additional, Sarter, H, additional, Savoye, G, additional, Turck, D, additional, and Fumery, M, additional

Published
2023
Full Text
View/download PDF

24. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study

Author

Hochart, A, Gower-Rousseau, C, Sarter, H, Fumery, M, Ley, D, Spyckerelle, C, Peyrin-Biroulet, L, Laberenne, J-E, Vasseur, F, Savoye, G, Turck, D, Andre, JM, Antonietti, M, Aouakli, A, Armand, A, Aroichane, I, Assi, F, Aubet, JP, Auxenfants, E, Ayafi-Ramelot, F, Azzouzi, K, Bankovski, D, Barbry, B, Bardoux, N, Baron, P, Baudet, A, Bazin, B, Bebahani, A, Becqwort, JP, Benet, V, Benali, H, Benguigui, C, Ben Soussan, E, Bental, A, Berkelmans, I, Bernet, J, Bernou, K, Bernou-Dron, C, Bertot, P, Bertiaux-Vandaële, N, Bertrand, V, Billoud, E, Biron, N, Bismuth, B, Bleuet, M, Blondel, F, Blondin, V, Bohon, P, Boniface, E, Bonnière, P, Bonvarlet, E, Bonvarlet, P, Boruchowicz, A, Bostvironnois, R, Boualit, M, Bouche, B, Boudaillez, C, Bourgeaux, C, Bourgeois, M, Bourguet, A, Bourienne, A, Branche, J, Bray, G, Brazier, F, Breban, P, Bridenne, M, Brihier, H, Brung-Lefebvre, V, Bulois, P, Burgiere, P, Butel, J, Canva, JY, Canva-Delcambre, V, Capron, JP, Cardot, F, Carpentier, P, Cartier, E, Cassar, JF, Cassagnou, M, Castex, JF, Catala, P, Cattan, S, Catteau, S, Caujolle, B, Cayron, G, Chandelier, C, Chantre, M, Charles, J, Charneau, T, Chavance-Thelu, M, Chirita, D, Choteau, A, Claerbout, JF, Clergue, PY, Coevoet, H, Cohen, G, Collet, R, Colombel, JF, Coopman, S, Corvisart, J, Cortot, A, Couttenier, F, Crinquette, JF, Crombe, V, Dadamessi, I, Dapvril, V, Davion, T, Dautreme, S, Debas, J, Degrave, N, Dehont, F, Delatre, C, Delcenserie, R, Delette, O, Delgrange, T, Delhoustal, L, Delmotte, JS, Demmane, S, Deregnaucourt, G, Descombes, P, Desechalliers, JP, Desmet, P, Desreumaux, P, Desseaux, G, Desurmont, P, Devienne, A, Devouge, E, Devred, M, Devroux, A, Dewailly, A, Dharancy, S, Di Fiore, A, Djeddi, D, Djedir, R, Dreher-Duwat, ML, Dubois, R, Dubuque, C, Ducatillon, P, Duclay, J, Ducrocq, B, Ducrot, F, Ducrotte, P, Dufilho, A, Duhamel, C, Dujardin, D, Dumant-Forest, C, Dupas, JL, Dupont, F, Duranton, Y, Duriez, A, El Achkar, K, El Farisi, M, Elie, C, Elie-Legrand, MC, Elkhaki, A, Eoche, M, Evrard, D, Evrard, JP, Fatome, A, Filoche, B, Finet, L, Flahaut, M, Flamme, C, Foissey, D, Fournier, P, Foutrein-Comes, MC, Foutrein, P, Fremond, D, Frere, T, Gallet, P, Gamblin, C, Ganga, S, Gerard, R, Geslin, G, Gheyssens, Y, Ghossini, N, Ghrib, S, Gilbert, T, Gillet, B, Godard, D, Godard, P, Godchaux, JM, Godchaux, R, Goegebeur, G, Goria, O, Gottrand, F, Gower, P, Grandmaison, B, Groux, M, Guedon, C, Guillard, JF, Guillem, L, Guillemot, F, Guimberd, D, Haddouche, B, Hakim, S, Hanon, D, Hautefeuille, V, Heckestweiller, P, Hecquet, G, Hedde, JP, Hellal, H, Henneresse, PE, Heyman, B, Heraud, M, Herve, S, Hochain, P, Houssin-Bailly, L, Houcke, P, Huguenin, B, Iobagiu, S, Ivanovic, A, Iwanicki-Caron, I, Janicki, E, Jarry, M, Jeu, J, Joly, JP, Jonas, C, Katherin, F, Kerleveo, A, Khachfe, A, Kiriakos, A, Kiriakos, J, Klein, O, Kohut, M, Kornhauser, R, Koutsomanis, D, Laffineur, G, Lagarde, M, Lalanne, A, Lannoy, P, Lapchin, J, Laprand, M, Laude, D, Leblanc, R, Lecieux, P, Leclerc, N, Le Couteulx, C, Ledent, J, Lefebvre, J, Lefiliatre, P, Legrand, C, Le Grix, A, Lelong, P, Leluyer, B, Lenaerts, C, Lepileur, L, Leplat, A, Lepoutre-Dujardin, E, Leroi, H, Leroy, MY, Lesage, JP, Lesage, X, Lesage, J, Lescanne-Darchis, I, Lescut, J, Lescut, D, Leurent, B, Levy, P, Lhermie, M, Lion, A, Lisambert, B, Loire, F, Louf, S, Louvet, A, Luciani, M, Lucidarme, D, Lugand, J, Macaigne, O, Maetz, D, Maillard, D, Mancheron, H, Manolache, O, Marks-Brunel, AB, Marti, R, Martin, F, Martin, G, Marzloff, E, Mathurin, P, Mauillon, J, Maunoury, V, Maupas, JL, Mesnard, B, Metayer, P, Methari, L, Meurisse, B, Meurisse, F, Michaud, L, Mirmaran, X, Modaine, P, Monthe, A, Morel, L, Mortier, PE, Moulin, E, Mouterde, O, Mudry, J, Nachury, M, NʼGuyen Khac, E, Notteghem, B, Ollevier, V, Ostyn, A, Ouraghi, A, Ouvry, D, Paillot, B, Panien-Claudot, N, Paoletti, C, Papazian, A, Parent, B, Pariente, B, Paris, JC, Patrier, P, Paupart, L, Pauwels, B, Pauwels, M, Petit, R, Piat, M, Piotte, S, Plane, C, Plouvier, B, Pollet, E, Pommelet, P, Pop, D, Pordes, C, Pouchain, G, Prades, P, Prevost, A, Prevost, JC, Quesnel, B, Queuniet, AM, Quinton, JF, Rabache, A, Rabelle, P, Raclot, G, Ratajczyk, S, Rault, D, Razemon, V, Reix, N, Revillon, M, Richez, C, Robinson, P, Rodriguez, J, Roger, J, Roux, JM, Rudelli, A, Saber, A, Schlosseberg, P, Segrestin, M, Seguy, D, Serin, M, Seryer, A, Sevenet, F, Shekh, N, Silvie, J, Simon, V, Talbodec, N, Techy, A, Thelu, JL, Thevenin, A, Thiebault, H, Thomas, J, Thorel, JM, Tielman, G, Tode, M, Toisin, J, Tonnel, J, Touchais, JY, Touze, Y, Tranvouez, JL, Triplet, C, Uhlen, S, Vaillant, E, Valmage, C, Vanco, D, Vandamme, H, Vanderbecq, E, Vander Eecken, E, Vandermolen, P, Vandevenne, P, Vandeville, L, Vandewalle, A, Vandewalle, C, Vaneslander, P, Vanhoove, JP, Vanrenterghem, A, Varlet, P, Vasies, I, Verbiese, G, Vernier-Massouille, G, Vermelle, P, Verne, C, Vezilier-Cocq, P, Vigneron, B, Vincendet, M, Viot, J, Voiment, YM, Wacrenier, A, Waeghemaecker, L, Wallez, JY, Wantiez, M, Wartel, F, Weber, J, Willocquet, JL, Wizla, N, Wolschies, E, Zalar, A, Zaouri, B, Zellweger, A, and Ziade, C

Published
2017
Full Text
View/download PDF

26. Technical Summary

Author

Pörtner, Hans-Otto, Roberts, D.C., Adams, H., Adelekan, I., Adler, C., Adrian, R., Aldunce, Paulina, Ali, Elham, Ara Begum, R., Bednar-Friedl, B., Kerr, Rachel Bezner, Biesbroek, G.R., Birkmann, J., Bowen, K., Caretta, M.A., Carnicer, Jofre, Castellanos, Edwin, Cheong, T.S., Chow, W., Cissé, Guéladio, Clayton, S., Constable, A., Cooley, S.R., Costello, M.J., Craig, M., Cramer, W., Dawson, R., Dodman, D., Efitre, J., Garschagen, M., Gilmore, E.A., Glavovic, B.C., Gutzler, D., Haasnoot, M., Harper, S., Hasegawa, T., Hayward, B., Hicke, J.A., Hirabayashi, Y., Huang, C., Kalaba, K., Kiessling, W., Kitoh, A., Lasco, R., Lawrence, J., Lemos, M.F., Lempert, R., Lennard, C., Ley, D., Lissner, T., Liu, Q., Liwenga, E., Lluch-Cota, Salvador, Löschke, S., Lucatello, S., Luo, Y., Mackey, B., Mintenbeck, Katja, Mirzabaev, A., Möller, V., Moncassim Vale, Mariana, Morecroft, M.D., Mortsch, L., Mukherji, A., Mustonen, Tero, Mycoo, Michelle, Nalau, J., New, M., Okem, A., Ometto, J.P., O'Neill, B., Pandey, R., Parmesan, Camille, Pelling, Mark, Pinho, P.F., Pinnegar, J., Poloczanska, E.S., Prakash, A., Preston, B., Racault, Marie-Fanny, Reckien, Diana, Revi, A., Rose, S.K., Schipper, E.L.F., Schmidt, D.N., Schoeman, D., Shaw, R., Simpson, N.P., Singh, C., Solecki, W., Stringer, L., Totin, E., Trisos, C.H., Trisurat, Y., van Aalst, M., Viner, D., Wairiu, Morgan, Warren, R., Wester, P., Wrathall, David, Zaiton Ibrahim, Zelina, Pörtner, Hans-Otto, Roberts, D.C., Adams, H., Adelekan, I., Adler, C., Adrian, R., Aldunce, Paulina, Ali, Elham, Ara Begum, R., Bednar-Friedl, B., Kerr, Rachel Bezner, Biesbroek, G.R., Birkmann, J., Bowen, K., Caretta, M.A., Carnicer, Jofre, Castellanos, Edwin, Cheong, T.S., Chow, W., Cissé, Guéladio, Clayton, S., Constable, A., Cooley, S.R., Costello, M.J., Craig, M., Cramer, W., Dawson, R., Dodman, D., Efitre, J., Garschagen, M., Gilmore, E.A., Glavovic, B.C., Gutzler, D., Haasnoot, M., Harper, S., Hasegawa, T., Hayward, B., Hicke, J.A., Hirabayashi, Y., Huang, C., Kalaba, K., Kiessling, W., Kitoh, A., Lasco, R., Lawrence, J., Lemos, M.F., Lempert, R., Lennard, C., Ley, D., Lissner, T., Liu, Q., Liwenga, E., Lluch-Cota, Salvador, Löschke, S., Lucatello, S., Luo, Y., Mackey, B., Mintenbeck, Katja, Mirzabaev, A., Möller, V., Moncassim Vale, Mariana, Morecroft, M.D., Mortsch, L., Mukherji, A., Mustonen, Tero, Mycoo, Michelle, Nalau, J., New, M., Okem, A., Ometto, J.P., O'Neill, B., Pandey, R., Parmesan, Camille, Pelling, Mark, Pinho, P.F., Pinnegar, J., Poloczanska, E.S., Prakash, A., Preston, B., Racault, Marie-Fanny, Reckien, Diana, Revi, A., Rose, S.K., Schipper, E.L.F., Schmidt, D.N., Schoeman, D., Shaw, R., Simpson, N.P., Singh, C., Solecki, W., Stringer, L., Totin, E., Trisos, C.H., Trisurat, Y., van Aalst, M., Viner, D., Wairiu, Morgan, Warren, R., Wester, P., Wrathall, David, and Zaiton Ibrahim, Zelina

Published
2022

29. Long-term effectiveness of anti-TNF therapy in pediatric-onset inflammatory bowel diseases: a population-based study

Author

Fumery, Mathurin, Savoye, G., Ley, D., Dupont, C., Bertrand, V., Spyckerelle, C., Guillon, N., Desreumaux, P., Gower-Rousseau, C., Sarter, H., Turck, D., Leroyer, A., CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Jeanne de Flandre [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe Hospitalier du Havre, Unité Pédiatrique [Saint-Vincent de Paul Lille], Hôpital Saint-Vincent de Paul, Hôpital Claude Huriez [Lille], CHU Lille, Service d'Epidémiologie et de Santé Publique [Lille], Maison Régionale de la Recherche Clinique [Lille], Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut National de la Santé et de la Recherche Médicale (INSERM), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022

30. Natural history of anal ulcerations in pediatric-onset Crohn's Disease: A population-based study

Author

Mortreux, P., Leroyer, A., Dupont, C., Ley, D., Bertrand, V., Spyckerelle, C., Guillon, N., Desreumaux, P., Gower-Rousseau, C., Savoye, G., Fumery, Mathurin, Turck, D., Siproudhis, L., Sarter, H., DESSAIVRE, Louise, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Jeanne de Flandre [Lille], Université de Lille, Groupe Hospitalier du Havre, Unité Pédiatrique [Saint-Vincent de Paul Lille], Hôpital Saint-Vincent de Paul, Centre d'Études Biologiques de Chizé - UMR 7372 (CEBC), La Rochelle Université (ULR)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Claude Huriez [Lille], CHU Lille, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), SFNCP, GREP, IHFIH UPRES EA 3859, Service d'Epidémiologie et de Santé Publique [Lille], and Maison Régionale de la Recherche Clinique [Lille]

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022

31. Cross-Chapter Box FEASIB | Feasibility Assessment of Adaptation Options: An Update of the SR1.5

Author

Ley, D., Adams, H., Araos, M., Basu, R., Bazaz, A., Conte, L., Davis, K., Dockendorff, C., Ford, J., Fuss, S., Elisabeth, G.A., Guillén Bolaños, T., Hoegh-Guldberg, O., Howden, M., Kalyan, B., Moro, L., Mosurska, A., Mechler, R., Portuga-Pereira, J., Revi, A., Sharma, S., Sietsma, A.J., Singh, C. Triacca A., van Bavel, B., Villaverde Canosa, I., Babiker, M, Bertoldi P., Cohen, B., Cowie, A., de Kleijne, K., Emmet-Booth, J., Garg, A., Nabuurs G.-J., Frossard Pereira de Lucena, A., Leip, A., Nilsson, L..J., Smith, P., Steg, L., and Sugiyama, M.

Published
2022

33. OP35 Natural history of anal ulcerations in pediatric-onset Crohn’s Disease: A population-based study

Author

Mortreux, P, primary, Leroyer, A, additional, Dupont, C, additional, Ley, D, additional, Bertrand, V, additional, Spyckerelle, C, additional, Guillon, N, additional, Desreumaux, P, additional, Gower-Rousseau, C, additional, Savoye, G, additional, Fumery, M, additional, Turck, D, additional, Siproudhis, L, additional, and Sarter, H, additional

Published
2022
Full Text
View/download PDF

41. Cell-free oxidized hemoglobin drives reactive oxygen species production and pro-inflammation in an immature primary rat mixed glial cell culture

Author

Agyemang AA, Kvist SV, Brinkman N, Gentinetta T, Illa-Armengol M, Ortenlöf N, Holmqvist B, Ley D, and Gram M

Subjects
Redox, Intraventricular hemorrhage, Haptoglobin, Mixed glial cells, Hemoglobin metabolites, Hemorrhagic cerebrospinal fluid
Abstract

BACKGROUND: Germinal matrix intraventricular hemorrhage (GM-IVH) is associated with deposition of redox active cell-free hemoglobin (Hb), derived from hemorrhagic cerebrospinal fluid (CSF), in the cerebrum and cerebellum. In a recent study, using a preterm rabbit pup model of IVH, intraventricularly administered haptoglobin (Hp), a cell-free Hb scavenger, partially reversed the damaging effects observed following IVH. Together, this suggests that cell-free Hb is central in the pathophysiology of the injury to the immature brain following GM-IVH. An increased understanding of the causal pathways and metabolites involved in eliciting the damaging response following hemorrhage is essential for the continued development and implementation of neuroprotective treatments of GM-IVH in preterm infant. METHODS: We exposed immature primary rat mixed glial cells to hemorrhagic CSF obtained from preterm human infants with IVH (containing a mixture of Hb-metabolites) or to a range of pure Hb-metabolites, incl. oxidized Hb (mainly metHb with iron in Fe(3+)), oxyHb (mainly Fe(2+)), or low equivalents of heme, with or without co-administration with human Hp (a mixture of isotype 2-2/2-1). Following exposure, cellular response, reactive oxygen species (ROS) generation, secretion and expression of pro-inflammatory cytokines and oxidative markers were evaluated. RESULTS: Exposure of the glial cells to hemorrhagic CSF as well as oxidized Hb, but not oxyHb, resulted in a significantly increased rate of ROS production that positively correlated with the rate of production of pro-inflammatory and oxidative markers. Congruently, exposure to oxidized Hb caused a disintegration of the polygonal cytoskeletal structure of the glial cells in addition to upregulation of F-actin proteins in microglial cells. Co-administration of Hp partially reversed the damaging response of hemorrhagic CSF and oxidized Hb. CONCLUSION: Exposure of mixed glial cells to oxidized Hb initiates a pro-inflammatory and oxidative response with cytoskeletal disintegration. Early administration of Hp, aiming to minimize the spontaneous autoxidation of cell-free oxyHb and liberation of heme, may provide a therapeutic benefit in preterm infant with GM-IVH.

Published
2021

43. Impact of therapeutic strategies on intestinal resection rate in paediatric inflammatory bowel diseases: A population-based cohort study over a 24-year period (1988-2011)

Author

Ley, D., Leroyer, A., Dupont, C., Sarter, H., Bertrand, V., Spyckerelle, C., Guillon, N., Pariente, B., Savoye, G., Turck, D., Gower-Rousseau, C., Fumery, Mathurin, Grp, Epimad, Hôpital Jeanne de Flandre [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, Hydrosciences Montpellier (HSM), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d'Epidémiologie et de Santé Publique [Lille], Groupe Hospitalier du Havre, Unité Pédiatrique [Saint-Vincent de Paul Lille], Hôpital Saint-Vincent de Paul, Hôpital Claude Huriez [Lille], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

44. Loss and Damage and limits to adaptation: recent IPCC insights and implications for climate science and policy

Author

Mechler, Reinhard, Singh, C, Ebi, K, Djalante, R, Thomas, A, James, R, Tschakert, P, Wewerinke-Singh, M, Schinko, T, Ley, D, Nalau, J, Bouwer, L M, Huggel, Christian, Huq, S, Linnerooth-Bayer, J, Surminski, S, Pinho, P, Jones, R, Boyd, E, Revi, A, Mechler, Reinhard, Singh, C, Ebi, K, Djalante, R, Thomas, A, James, R, Tschakert, P, Wewerinke-Singh, M, Schinko, T, Ley, D, Nalau, J, Bouwer, L M, Huggel, Christian, Huq, S, Linnerooth-Bayer, J, Surminski, S, Pinho, P, Jones, R, Boyd, E, and Revi, A

Abstract

Recent evidence shows that climate change is leading to irreversible and existential impacts on vulnerable communities and countries across the globe. Among other effects, this has given rise to public debate and engagement around notions of climate crisis and emergency. The Loss and Damage (L&D) policy debate has emphasized these aspects over the last three decades. Yet, despite institutionalization through an article on L&D by the United Nations Framework Convention on Climate Change (UNFCCC) in the Paris Agreement, the debate has remained vague, particularly with reference to its remit and relationship to adaptation policy and practice. Research has recently made important strides forward in terms of developing a science perspective on L&D. This article reviews insights derived from recent publications by the Intergovernmental Panel on Climate Change (IPCC) and others, and presents the implications for science and policy. Emerging evidence on hard and soft adaptation limits in certain systems, sectors and regions holds the potential to further build momentum for climate policy to live up to the Paris ambition of stringent emission reductions and to increase efforts to support the most vulnerable. L&D policy may want to consider actions to extend soft adaptation limits and spur transformational, that is, non-standard risk management and adaptation, so that limits are not breached. Financial, technical, and legal support would be appropriate for instances where hard limits are transgressed. Research is well positioned to further develop robust evidence on critical and relevant risks at scale in the most vulnerable countries and communities, as well as options to reduce barriers and limits to adaptation.

Published
2020

50. OP02 Impact of therapeutic strategies on intestinal resection rate in paediatric inflammatory bowel diseases: A population-based cohort study over a 24-year period (1988–2011)

Author

Ley, D, primary, Leroyer, A, additional, Dupont, C, additional, Sarter, H, additional, Bertrand, V, additional, Spyckerelle, C, additional, Guillon, N, additional, Pariente, B, additional, Savoye, G, additional, Turck, D, additional, Gower-Rousseau, C, additional, and Fumery, M, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results